Literature DB >> 8706230

Prevalence of anti-Rift-Valley-fever IgM antibody in abattoir workers in the Nile delta during the 1993 outbreak in Egypt.

R Abu-Elyazeed1, S el-Sharkawy, J Olson, B Botros, A Soliman, A Salib, C Cummings, R Arthur.   

Abstract

In the early summer of 1993, an outbreak of Rift Valley fever (RVF) was reported among both humans and animals in Aswan Governorate, Upper Egypt. To determine whether RVF infection had spread to the Nile delta region of the country, we carried out a cross-sectional survey of 1181 occupationally exposed abattoir workers (97% male; age 10-72 years) in 15 governorates of Egypt in November 1993. The overall prevalence of anti-RVF virus IgM antibody was 2% (range: 0% (7 governorates) to 10%). The highest prevalences were in Ismailia (10%) and Sharqîya (8%) Governorates. None of the seropositive subjects reported having experienced an episode of fever in the 2 months prior to the study. The prevalence of antibody was significantly higher (P < 0.05) among workers employed in high-risk jobs such as cutting animals' throats (relative risk (RR = 2.24)) and handling animal parts (RR = 2.37). The findings suggest that abattoir workers represent a useful sentinel population for surveillance of RVF.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8706230      PMCID: PMC2486897     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  6 in total

1.  Possible vectors of Rift Valley fever in Kenya.

Authors:  F G Davies; R B Highton
Journal:  Trans R Soc Trop Med Hyg       Date:  1980       Impact factor: 2.184

2.  Epidemic Rift Valley fever in Egypt: observations of the spectrum of human illness.

Authors:  L W Laughlin; J M Meegan; L J Strausbaugh; D M Morens; R H Watten
Journal:  Trans R Soc Trop Med Hyg       Date:  1979       Impact factor: 2.184

3.  Rift Valley Fever and its epidemiology in Egypt: a review.

Authors:  N H Ghoneim; G T Woods
Journal:  J Med       Date:  1983

4.  Detection of human immunoglobulins G and M antibodies to Rift Valley fever virus by enzyme-linked immunosorbent assay.

Authors:  B Niklasson; C J Peters; M Grandien; O Wood
Journal:  J Clin Microbiol       Date:  1984-02       Impact factor: 5.948

5.  An epizootic of Rift Valley fever in Egypt in 1977.

Authors:  J M Meegan; H Hoogstraal; M I Moussa
Journal:  Vet Rec       Date:  1979-08-11       Impact factor: 2.695

6.  Recurrence of Rift Valley fever in Egypt.

Authors:  R R Arthur; M S el-Sharkawy; S E Cope; B A Botros; S Oun; J C Morrill; R E Shope; R G Hibbs; M A Darwish; I Z Imam
Journal:  Lancet       Date:  1993-11-06       Impact factor: 79.321

  6 in total
  28 in total

Review 1.  Emerging infectious diseases: the Bunyaviridae.

Authors:  Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

2.  Risk factors for severe Rift Valley fever infection in Kenya, 2007.

Authors:  Amwayi S Anyangu; L Hannah Gould; Shahnaaz K Sharif; Patrick M Nguku; Jared O Omolo; David Mutonga; Carol Y Rao; Edith R Lederman; David Schnabel; Janusz T Paweska; Mark Katz; Allen Hightower; M Kariuki Njenga; Daniel R Feikin; Robert F Breiman
Journal:  Am J Trop Med Hyg       Date:  2010-08       Impact factor: 2.345

3.  An outbreak of Rift Valley fever in Northeastern Kenya, 1997-98.

Authors:  Christopher W Woods; Adam M Karpati; Thomas Grein; Noel McCarthy; Peter Gaturuku; Eric Muchiri; Lee Dunster; Alden Henderson; Ali S Khan; Robert Swanepoel; Isabelle Bonmarin; Louise Martin; Philip Mann; Bonnie L Smoak; Michael Ryan; Thomas G Ksiazek; Ray R Arthur; Andre Ndikuyeze; Naphtali N Agata; Clarence J Peters
Journal:  Emerg Infect Dis       Date:  2002-02       Impact factor: 6.883

4.  Rift Valley fever virus(Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention.

Authors:  Michel Pepin; Michele Bouloy; Brian H Bird; Alan Kemp; Janusz Paweska
Journal:  Vet Res       Date:  2010 Nov-Dec       Impact factor: 3.683

Review 5.  Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines.

Authors:  Michele Bouloy; Ramon Flick
Journal:  Antiviral Res       Date:  2009-08-12       Impact factor: 5.970

6.  Development of Rift valley fever encephalitis in rats is mediated by early infection of olfactory epithelium and neuroinvasion across the cribriform plate.

Authors:  Devin A Boyles; Madeline M Schwarz; Joseph R Albe; Cynthia M McMillen; Katherine J O'Malley; Douglas S Reed; Amy L Hartman
Journal:  J Gen Virol       Date:  2021-02       Impact factor: 3.891

7.  Combining hydrology and mosquito population models to identify the drivers of Rift Valley fever emergence in semi-arid regions of West Africa.

Authors:  Valérie Soti; Annelise Tran; Pascal Degenne; Véronique Chevalier; Danny Lo Seen; Yaya Thiongane; Mawlouth Diallo; Jean-François Guégan; Didier Fontenille
Journal:  PLoS Negl Trop Dis       Date:  2012-08-21

8.  Identifying landscape features associated with Rift Valley fever virus transmission, Ferlo region, Senegal, using very high spatial resolution satellite imagery.

Authors:  Valérie Soti; Véronique Chevalier; Jonathan Maura; Agnès Bégué; Camille Lelong; Renaud Lancelot; Yaya Thiongane; Annelise Tran
Journal:  Int J Health Geogr       Date:  2013-03-01       Impact factor: 3.918

9.  Aerosol exposure to Rift Valley fever virus causes earlier and more severe neuropathology in the murine model, which has important implications for therapeutic development.

Authors:  Christopher Reed; Kenny Lin; Catherine Wilhelmsen; Brian Friedrich; Aysegul Nalca; Ashley Keeney; Ginger Donnelly; Joshua Shamblin; Lisa E Hensley; Gene Olinger; Darci R Smith
Journal:  PLoS Negl Trop Dis       Date:  2013-04-04

10.  SEROPREVALENCE OF RIFT VALLEY FEVER AMONG SLAUGHTERHOUSE PERSONNEL IN MAKKAH DURING HAJJ 1419h (1999).

Authors:  A H Turkistany; A G Mohamed; N Al-Hamdan
Journal:  J Family Community Med       Date:  2001-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.